Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Verastem Inc (NQ: VSTM ) 2.960 +0.300 (+11.28%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Verastem Inc < Previous 1 2 3 4 Next > Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021 September 19, 2021 From Verastem Oncology Via Business Wire Verastem Oncology to Present at Upcoming Investor Conferences September 07, 2021 From Verastem Oncology Via Business Wire Verastem Oncology Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress August 02, 2021 From Verastem Oncology Via Business Wire Verastem Oncology Announces Updated Phase 1/2 FRAME Study Data in Low Grade Serous Ovarian Cancer Selected for a Mini Oral Presentation at the European Society of Medical Oncology Congress 2021 July 27, 2021 From Verastem Oncology Via Business Wire Verastem Oncology Announces Conversion of Senior Notes Eliminating Substantially All Outstanding Debt July 19, 2021 From Verastem Oncology Via Business Wire Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 06, 2021 From Verastem Oncology Via Business Wire Verastem Oncology Appoints Paul Bunn, M.D., and Lesley Solomon to Board of Directors June 24, 2021 From Verastem Oncology Via Business Wire Verastem Oncology to Present at the 2021 Jefferies Virtual Healthcare Conference May 25, 2021 From Verastem, Inc. Via Business Wire Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer May 24, 2021 From Verastem, Inc. Via Business Wire Verastem Oncology Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress May 11, 2021 From Verastem Oncology Via Business Wire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.